Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04963283
Recruitment Status : Recruiting
First Posted : July 15, 2021
Last Update Posted : December 2, 2021
National Cancer Institute (NCI)
Criterium, Inc.
Bristol-Myers Squibb
Information provided by (Responsible Party):
University of Colorado, Denver

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 9, 2024
Estimated Study Completion Date : February 9, 2025